Indeed, a large multi-centre clinical trial, CREDENCE (The Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy, clinicaltrials.gov identifier: NCT02065791) to address the possible renoprotective properties of SGLT2 inhibition, is currently being conducted in patients with diabetic kidney disease. Here, SLC5A2 is linked to diabetic kidney disease.